BURSTRory de Vries, an associate professor of virology in the Netherlands, was lifting weights at the gym when he noticed a WhatsApp message from his research partners at Columbia University, telling him his research funding had been cancelled. The next day he received the official email: “Hi Rory, Columbia has received a termination notice for this contract, including all subcontracts,” it stated. “Unfortunately, we must advise you to immediately stop work and cease incurring charges on this subcontract.”
De Vries was disappointed, though not surprised—his team knew this might happen under the new Trump administration. His projects focused on immune responses and a new antiviral treatment for respiratory viruses like Covid-19. Animals had responded well in pre-clinical trials, and he was about to explore the next steps for applications in humans. But the news, which he received in March, left him with a cascade of questions: What would happen to the doctoral student he had just hired for his project, a top candidate plucked from a pool of some 300 aspiring scientists? How would his team comply with local Dutch law, which, unlike the US, forbids terminating a contract without cause or notice? And what did the future hold for his projects, two of which contained promising data for treating Covid-19 and other respiratory illnesses in humans?
It was all up in the air, leaving de Vries, who works at the Erasmus Medical Center in Rotterdam and whose research has appeared in top-tier publications scrambling for last-minute funding from the Dutch government or the European Union.